Last update: June 4, 2016

Διλτιαζέμη υδροχλωρική

Very Low Risk for breastfeeding


Safe. Compatible.
Not risky for breastfeeding or infant.

It is excreted in breast milk in a clinically non-significant amount (Okada 85)
Two 6 months-old breastfed twins whose mother was treated with diltiazem did not get into health problems (Lubbe 87)

Evidence on other antihypertensive drugs of the same family with similar structure, pharmacokinetics and action profile (nifedipine, nimodipine, nicardipine) has shown that they are excreted into milk in non-significant amount.
Diltiazem does not have any influence on prolactin production.

Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug should be used, especially during the neonatal period and/or in case of premature infants.

American Academy of Pediatrics: medication usually compatible with breastfeeding.

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Διλτιαζέμη υδροχλωρική is Diltiazem Hydrochloride in Greek.

Is written in other languages:

Group

Διλτιαζέμη υδροχλωρική belongs to this group or family:

Tradenames

Main tradenames from several countries containing Διλτιαζέμη υδροχλωρική in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 42 ± 18 %
Molecular weight 451 daltons
Protein Binding 80 %
VD 5,3 ± 1,7 l/Kg
Tmax 3 - 8 hours
T1/2 3,2 ± 1,3 hours
M/P ratio 1 -
Theoretical Dose 0.03 mg/Kg/d
Relative Dose 0,9 - ,5 %
Relat.Ped.Dose 1,5 %

References

  1. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Abstract
  2. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  3. Velardo A, Ricci S, Zironi C, Pantaleoni M, Zizzo G, Badiali A, Marrama P. Effects of prolonged treatment with diltiazem on pituitary secretion of luteinizing hormone, follicle-stimulating hormone, thyrotropin and prolactin. Horm Res. 1992 Abstract
  4. Lubbe WF. Use of diltiazem during pregnancy. N Z Med J. 1987 Abstract
  5. Okada M, Inoue H, Nakamura Y, Kishimoto M, Suzuki T. Excretion of diltiazem in human milk. N Engl J Med. 1985 Abstract
  6. Hermann P, Rodger SD, Remones G, Thenot JP, London DR, Morselli PL. Pharmacokinetics of diltiazem after intravenous and oral administration. Eur J Clin Pharmacol. 1983 Abstract

Total visits

713

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM